IBIO : AMEX : Health Care
$0.37 | %
Today's Range: 0.3521 - 0.37
Avg. Daily Volume: 103100.0
05/26/17 - 4:00 PM ET

Financial Analysis


IBIO INC's gross profit margin for the second quarter of its fiscal year 2017 has significantly decreased when compared to the same period a year ago. Sales and net income fell significantly, underperforming compared to the average company in its industry. IBIO INC is extremely liquid. Currently, the Quick Ratio is 8.80 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.

At the same time, stockholders' equity ("net worth") has significantly decreased by 47.28% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q2 FY17 Q2 FY16
Net Sales ($mil)0.080.14
EBITDA ($mil)-2.91-2.16
EBIT ($mil)-3.32-2.25
Net Income ($mil)-3.23-2.25


Balance Sheet Q2 FY17 Q2 FY16
Cash & Equiv. ($mil)16.336.73
Total Assets ($mil)44.199.42
Total Debt ($mil)25.350.0
Equity ($mil)4.157.88


Profitability Q2 FY17 Q2 FY16
Gross Profit Margin-3679.75-1540.0
EBITDA Margin-3679.74-1540.0
Operating Margin-4203.8-1605.71
Sales Turnover0.020.1
Return on Assets-27.16-80.85
Return on Equity-289.01-96.63
Debt Q2 FY17 Q2 FY16
Current Ratio8.974.68
Debt/Capital0.860.0
Interest Expense0.480.0
Interest Coverage-6.880.0


Share Data Q2 FY17 Q2 FY16
Shares outstanding (mil)89.1177.33
Div / share0.00.0
EPS-0.04-0.03
Book value / share0.050.1
Institutional Own % n/a n/a
Avg Daily Volume102709.0106661.0

Valuation


SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. To use another comparison, its price-to-book ratio of 7.94 indicates a significant premium versus the S&P 500 average of 3.06 and a significant discount versus the industry average of 10.06. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, IBIO INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
IBIO NM Peers 38.69   IBIO NM Peers 44.11

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

IBIO's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

IBIO's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
IBIO NA Peers 22.54   IBIO NA Peers 0.48

Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.

Ratio not available.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
IBIO 7.94 Peers 10.06   IBIO -55.55 Peers -14.63

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

IBIO is trading at a discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, IBIO is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
IBIO 37.05 Peers 111.01   IBIO -10.03 Peers 455.32

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

IBIO is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

IBIO significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades